|
< Back to News Page
|
 |
Collegium Pharmaceutical Announces the Sale of AllerNaze™ to
Lupin
CUMBERLAND, RI-- (BUSINESS WIRE)- June 30, 2009 - Collegium
Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that Lupin
has acquired all worldwide rights to AllerNaze™ (triamcinolone acetonide, USP) Nasal
Spray, 50 mcg. AllerNaze™ is an aqueous based intranasal steroid (INS) product
indicated for the once daily treatment of nasal symptoms associated with both seasonal
allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children twelve
(12) years of age and older that was approved by the U.S. Food and Drug
Administration (FDA) in January 2009.
AllerNaze™ will compete in the approximately $2.5 billion a year United States market
for INS products for the treatment of allergic rhinitis. Allergic rhinitis is the most common
allergic condition and is increasing in prevalence. Allergic rhinitis is the medical term for
the inflammation of the nasal membranes and is characterized primarily by a runny
nose, which is the most common allergy symptom. SAR is the most common allergic
disease. Approximately 40 million Americans suffer from this condition.
"The acquisition of AllerNaze™ by Lupin, with its global pharmaceutical presence will
maximize the potential for this product in both the United States as well as around the
world” said Michael Heffernan, President of Collegium. "Completing this transaction with
Lupin allows us to continue to focus our efforts and resources on the further
development of our lead chronic pain product candidate, COL-003, that utilizes our
DETERx™ tamper resistant extended release technology. In addition, we intend to
continue to invest in building our Onset Therapeutics dermatology business".
Ferghana Partners acted as a financial advisor to the Company for the transaction.
About COL-003
COL-003 is a tamper resistant formulation of extended release oxycodone that
utilizes the Company's patented DETERx™ delivery technology. The product is
currently under clinical development pursuant to an active Investigational New Drug
Application and has received Fast Track Designation from the FDA. COL-003 is being
developed for the management of moderate to severe pain when a continuous, aroundthe-
clock analgesic is needed for an extended period of time.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the
development of proprietary, late stage pharmaceutical products. These products target
market opportunities through formulation based product improvements protected by
intellectual property (IP). Collegium is focused on building a portfolio of pain products
that incorporate its patent protected DETERx™ formulation platform that provides for
extended release and tamper resistance. The Company, through its subsidiary, Onset
Therapeutics (www.onsettx.com), develops and commercializes products for skin and
skin related disorders using its novel DELEVO™ Foam Technology. For more
information, visit the Company's website at www.collegiumpharma.com.
About Lupin
Headquartered in Mumbai, Lupin Ltd. is an innovation led transnational pharmaceutical
company producing a wide range of quality, affordable generic and branded
formulations and API's for the developed and developing markets of the world. The
Company has secured a global leadership position in Anti-TB, Cephalosporins (antiinfectives)
and Cardiovascular drugs (prils and statins) and has a notable presence in
the areas of diabetology, NSAIDs and Asthma. The Company's R & D endeavors have
resulted in significant progress in its NCE program. The Company's foray into Advanced
Drug Delivery Systems has resulted in the development of platform technologies that
are being used to develop value-added generic pharmaceuticals.
Currently positioned among the top five pharmaceutical companies of India, Lupin is
committed to achieve sustainable earnings and growth for all of its stakeholders. For the
financial year ended March 2009, the Company's revenues and profit after tax were Rs.
27,730 million (USD$ 694 million) and Rs. 4,083 million (USD$ 102 million) respectively.
For more information, please visit the Company's web site at www.lupinworld.com.
Lupin Pharmaceuticals, Inc. is the wholly owned US subsidiary of Lupin Ltd. With sales
and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated
to delivering quality brands and high quality affordable generic medicines.
|
|
